Actively Recruiting
Congenital Athymia Patient Registry
Led by Sumitomo Pharma Switzerland GmbH · Updated on 2025-08-19
75
Participants Needed
1
Research Sites
201 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).
CONDITIONS
Official Title
Congenital Athymia Patient Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pediatric patients diagnosed with Congenital Athymia
- Scheduled for RETHYMIC implantation within the next 30 days or treated with RETHYMIC within the previous 60 days
- Provided written informed consent by the patient, parent, or legal guardian
You will not qualify if you...
- Written informed consent cannot be obtained
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Duke University School of Medicine
Durham, North Carolina, United States, 27710
Actively Recruiting
Research Team
J
John Sleasman, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here